USANA Health Sciences Files 8-K on Financials

Ticker: USNA · Form: 8-K · Filed: 2024-04-30T00:00:00.000Z

Sentiment: neutral

Topics: financial-results, disclosure, sec-filing

Related Tickers: USNA

TL;DR

USANA Health Sciences dropped an 8-K on April 30th detailing their financial condition. Check it out.

AI Summary

On April 30, 2024, USANA Health Sciences, Inc. filed an 8-K report detailing its financial results and other relevant information. The filing includes financial statements and exhibits, indicating a report on the company's operational and financial condition.

Why It Matters

This filing provides investors with crucial updates on USANA Health Sciences' financial performance and operational status, enabling informed investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial disclosure filing (8-K) and does not inherently present new risks.

Key Players & Entities

USANA HEALTH SCIENCES, INC. (company) — Registrant
April 30, 2024 (date) — Date of Report
3838 West Parkway Boulevard (location) — Principal executive offices address
Salt Lake City, Utah (location) — Principal executive offices city and state
8019547100 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing for USANA Health Sciences?

The primary purpose is to report on the company's Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Statements and Exhibits as of April 30, 2024.

When was this 8-K report filed?

The report was filed on April 30, 2024.

What is USANA Health Sciences' principal executive office address?

The principal executive offices are located at 3838 West Parkway Boulevard, Salt Lake City, Utah 84120.

What is the SIC code for USANA Health Sciences?

The Standard Industrial Classification (SIC) code for USANA Health Sciences is 2833, which corresponds to MEDICINAL CHEMICALS & BOTANICAL PRODUCTS.

What is the company's state of incorporation?

USANA Health Sciences, Inc. is incorporated in Utah.

From the Filing

0000896264-24-000138.txt : 20240430 0000896264-24-000138.hdr.sgml : 20240430 20240430160814 ACCESSION NUMBER: 0000896264-24-000138 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240430 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: USANA HEALTH SCIENCES INC CENTRAL INDEX KEY: 0000896264 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870500306 STATE OF INCORPORATION: UT FISCAL YEAR END: 1230 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35024 FILM NUMBER: 24897209 BUSINESS ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 BUSINESS PHONE: 8019547100 MAIL ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. STREET 2: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 FORMER COMPANY: FORMER CONFORMED NAME: USANA INC DATE OF NAME CHANGE: 19930125 8-K 1 usna-20240430.htm 8-K usna-20240430 FALSE 0000896264 0000896264 2024-04-30 2024-04-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 30, 2024 USANA HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) Utah (State or other jurisdiction of incorporation) 001-35024 87-0500306 (Commission File No.) (IRS Employer Identification No.) 3838 West Parkway Boulevard Salt Lake City , Utah 84120 (Address of principal executive offices, Zip Code) Registrant's telephone number, including area code: ( 801 ) 954-7100 Check the appropriate box below if the Form 8-K ﬁling is intended to simultaneously satisfy the ﬁling obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share USNA New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as deﬁned in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised ﬁnancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 2.02    Results of Operations and Financial Condition. On April 30, 2024, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its financial results for the first quarter ended March 30, 2024. The release also announced that the Company will post a document titled “Management Commentary” on the Company’s website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company’s management team, before moving directly into questi